spacer
home > ebr > autumn 2017 > unleashing 3d
PUBLICATIONS
European Biopharmaceutical Review

Unleashing 3D

The last 10 years have seen a dramatic surge in the number of publications about organoids – but what are they and why is everyone talking about them? In simple terms, they are miniature organs grown in vitro in a near-physiological 3D environment. Unlike simple tissue cultures, they retain features of the organ they are derived from, including important structural and functional properties, and many believe that they could dramatically accelerate the understanding of human biology and disease progression.

Traditional 2D cell culture has brought great progress in understanding human development over the last 50 years. However, studying organogenesis in vitro has been hindered by the lack of appropriate systems that would allow the cell-to-cell interactions needed for organ formation. Organoids provide the accurate and physiologically relevant models that are needed to overcome this deficiency.

So-called organoids have now been derived from gut, kidney, pancreas, liver and brain tissue, and growing these mini-organs has been made possible by the recent advances in stem cell systems and the development of 3D support matrices. Thanks to this new technology, cells derived from stem cells or organ progenitors can self-organise through cell sorting and recapitulate the complexity of mammalian organogenesis in vitro in a way that is similar to how they do in vivo.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Colin Sanctuary is a biomedical engineer and Chief Executive Officer at QGel. Following his PhD in biomedical engineering at École Polytechnique Fédérale de Lausanne, Switzerland, Colin worked in product development and later in global marketing in the medical device and pharma industries. In 2009, he co-founded QGel with the aim of building a company that contributes to improving R&D productivity in pharma, particularly in the area of developing novel anticancer treatments.
spacer
Dr Colin Sanctuary
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Wickham Laboratories will be on Stand 8 at the 24th Annual Pharmig Conference in the Nottingham Belfry Hotel, November 16th & 17th


More info >>

White Papers

ConsulTech GmbH

ConsulTech GmbH

ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
More info >>

 
Industry Events

14th World Advanced Therapies & Regenerative Medicine Congress 2018

16-18 May 2018, Business Design Centre, London, United Kingdom

In May 2018 the World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement